Participants will take the study drug by mouth every day for several months, with regular visits to check for any side effects and to answer simple questionnaires. Researchers will monitor for any new health problems, serious problems, and specific symptoms related to the study drugs. They will also use a few rating tools to watch for movement‑related side effects and to assess thoughts of self‑harm, using the C-SSRS questionnaire and movement scales called the SAS, BARS, and AIMS. The study ends after the treatment period and a short follow‑up to confirm the safety findings.

The study will measure changes in Tregs, which are special white blood cells that help control the body’s immune response, by comparing blood samples taken at the start of the study and after 8 days. Children participating in the study will be followed for several months, with regular check-ups to assess various aspects of their development and behavior. These assessments will look at social skills, communication abilities, daily living skills, repetitive behaviors, attention, and overall functioning. Blood samples will be taken at different times throughout the study to measure immune cells.

During the study, doctors will also monitor for any unwanted effects of the treatment to ensure the safety of the children. The study will track how the treatment affects the children’s symptoms and their families’ well-being over time through questionnaires and observations completed by parents and healthcare professionals. The entire study is expected to continue for several years to gather enough information about how well the treatment works and how safe it is for young children with Autism Spectrum Disorder.

Participants in this study will receive the treatment through a method intended for use in the digestive tract. During the course of the trial, the progress of the symptoms and the physical response to the bacteria will be observed over time.

The purpose of this study is to check whether this cell treatment is safe for children with autism and digestive problems. The researchers want to carefully monitor any unwanted effects that might occur after the treatment. They will also look at whether the treatment might help improve behavior, communication skills, and quality of life related to digestive symptoms, although the main focus is on safety.

During the study, children will receive the cell treatment and will be closely watched for any reactions or side effects. The study team will use questionnaires to measure changes in daily living skills, communication abilities, and how digestive problems affect quality of life. All children in this study will receive the treatment, as this is an open label study, meaning everyone knows what treatment is being given.

The purpose of the study is to explore how this treatment might improve social interactions between children with autism and others. The study will involve children with autism participating in activities designed to measure their social engagement and responses. These activities will include both screen-based and real-life social interactions. The study will also look at changes in natural levels of oxytocin and cortisol, a stress hormone, in saliva samples after the treatment.

The trial will take place over a short period, with the treatment being administered once. The children will be observed for changes in their social behavior and physiological responses. The goal is to understand if the nasal spray can enhance social attunement, which means improving the ability to connect and interact with others, in children with autism. This research aims to provide insights into potential new ways to support social development in children with ASD.

The purpose of the study is to explore how this treatment might improve social interactions between children with ASD and others. Participants will receive the treatment through a nasal spray, and the study will observe changes in their social interactions. The study will also measure levels of oxytocin and another hormone called cortisol in saliva samples to see how they change after the treatment.

The study will take place over a short period, with participants receiving the treatment and then being observed for any changes in their social behavior. The goal is to better understand how oxytocin might help improve social skills in children with ASD, potentially leading to new ways to support those with the condition.

The purpose of the study is to evaluate the effect and safety of this treatment in improving digestive symptoms in children with autism. The study will follow the children over a period of time to see if their digestive symptoms improve and to monitor any side effects. The treatment will be given over a maximum period of 14 days, and the children’s progress will be checked at various points, including 18 weeks after the start of the study.

Throughout the study, parents and healthcare professionals will use different questionnaires and scales to assess changes in the children’s digestive symptoms and overall well-being. The study aims to see if there is a significant reduction in digestive issues and any improvement in the core symptoms of autism. The results will help determine if this treatment could be a beneficial option for children with autism and digestive problems.

Participants in the study will take the medication orally, which means swallowing the capsules. The study will monitor various health indicators, such as vital signs, weight, and heart function, to ensure the safety of the participants. Additionally, the study will assess any side effects that may arise during the treatment period. The goal is to gather information on how the medication affects the participants’ health and behavior over the course of a year.

Throughout the study, researchers will also evaluate changes in irritability levels using specific scales designed to measure behavior and improvement. This will help determine if pimavanserin is effective in reducing irritability in children and adolescents with ASD. The study aims to provide valuable insights into the long-term use of pimavanserin for managing irritability associated with ASD.

The study aims to determine if it is practical and safe to use oxytocin nasal spray in children aged 6 to 12 years who have severe autism and significant intellectual challenges. During the study, participants will receive either oxytocin nasal spray or a placebo (containing sodium chloride) in addition to their regular therapy. The treatment will be given daily through a nasal spray both at treatment centers and at home.

The treatment period lasts up to 12 weeks, during which children will receive regular medical check-ups. The study will test two different doses of oxytocin (4 and 8 international units) to evaluate how well children tolerate the treatment. Throughout the study, healthcare providers and parents will monitor the children’s response to the treatment and any changes in their behavior.

During the study, children will receive multiple doses of the oxytocin nasal spray over a period of time. The effects of the treatment will be monitored through various assessments, including observations of social communication changes and evaluations of autism symptoms by parents, caregivers, and teachers. Additionally, the study will measure stress levels using heart rate variability, which is a way to assess how the heart responds to stress. The study will also look at other aspects of behavior, such as repetitive behaviors, adaptive behavior, and sleep habits, to get a comprehensive understanding of the treatment’s impact.

The purpose of this study is to determine whether oxytocin can help improve the quality of life for children with autism and intellectual disabilities by addressing some of the core challenges they face. The study will provide valuable insights into the potential benefits of oxytocin as a treatment option for these conditions.

The purpose of the study is to explore the potential of Arbaclofen in enhancing social interactions and communication in young people with autism. Participants will receive the treatment over a period of time, and their responses will be monitored to assess any changes in their social behavior. The study will also look at specific biological markers, which are measurable indicators in the body, to see how they relate to the treatment’s effectiveness.

Throughout the study, participants will have regular visits to monitor their progress and any side effects. The trial will last for a maximum of 13 weeks, during which the participants’ social functions will be evaluated. This research hopes to provide valuable insights into how Arbaclofen can be used to support individuals with autism in their social development.

Participants in the study will receive a single dose of oxytocin through a nasal spray. The study will be conducted in a way that neither the participants nor the researchers know who receives the oxytocin or the placebo, ensuring unbiased results. The study will take place over three different periods, allowing researchers to observe any changes in brain activity and learning abilities after the administration of oxytocin.

The study will also look at other factors, such as heart rate variability, which is a measure of how the heart responds to different situations. This will help researchers understand if oxytocin has any additional effects on the body. The study aims to provide insights into whether oxytocin can improve learning and brain function in individuals with ASD.

Participants in the study will be divided into two groups. One group will receive dosing advice based on therapeutic drug monitoring, which means their medication levels will be regularly checked to adjust the dose as needed. The other group will receive the standard care, where the medication is given according to usual clinical practices without additional monitoring. The study will observe changes in body weight and other health indicators over a period of six months, with some assessments continuing up to twelve months.

Throughout the study, various health aspects will be evaluated, including changes in body mass index (BMI), behavior, quality of life, and any side effects. The study will also monitor levels of certain substances in the blood, such as glucose and cholesterol, and check for any involuntary movements. This research aims to provide valuable insights into how these medications can be used more effectively and safely in young individuals with autism spectrum disorder.

Participants in the study will be randomly assigned to receive either the pitolisant tablets or a placebo, which looks like the real medication but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased. The study will last for a period of 12 weeks, during which the participants will take the tablets orally.

Throughout the study, the effects of pitolisant on social communication and interaction will be assessed using a tool called the Social Responsiveness Scale Second Edition (SRS-2). The study will also monitor any changes in behavior, sleep patterns, and overall well-being. The goal is to determine if pitolisant can improve the core symptoms of ASD and to ensure that it is safe for use in children and adolescents. Participants will be closely monitored for any side effects or adverse reactions during the study period.

The purpose of the study is to evaluate how oxytocin affects social and repetitive behaviors in individuals with autism. Participants in the study will receive doses of oxytocin through a nasal spray twice a day for four weeks. Some participants will receive a placebo instead of oxytocin. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the oxytocin or the placebo during the trial period.

Throughout the study, changes in social behavior and repetitive actions will be monitored and assessed. The study aims to provide insights into whether oxytocin can help improve these behaviors in young people with autism. The trial will last for a total of four weeks, with participants being closely observed to ensure their safety and to gather data on the effects of the treatment.